Skip to search boxSkip to navigationSkip to main content

Protective Role of Kynurenine 3-Monooxygenase in Allograft Rejection and Tubular Injury in Kidney Transplantation

  • Randi Lassiter
    ,
  • Todd D. Merchen
    ,
  • Xuexiu Fang
    ,
  • Youli Wang(corresponding author)
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Abstract

<p>Renal tubular epithelial cells (TECs) are the primary targets of ischemia–reperfusion injury (IRI) and rejection by the recipient’s immune response in kidney transplantation (KTx). However, the molecular mechanism of rejection and IRI remains to be identified. Our previous study demonstrated that kynurenine 3-monooxygenase (KMO) and kynureninase were reduced in ischemia–reperfusion procedure and further decreased in rejection allografts among mismatched pig KTx. Herein, we reveal that TEC injury in acutely rejection allografts is associated with alterations of Bcl2 family proteins, reduction of tight junction protein 1 (TJP1), and TEC-specific KMO. Three cytokines, IFNγ, TNFα, and IL1β, reported in our previous investigation were identified as triggers of TEC injury by altering the expression of Bcl2, BID, and TJP1. Allograft rejection and TEC injury were always associated with a dramatic reduction of KMO. 3HK and 3HAA, as direct and downstream products of KMO, effectively protected TEC from injury via increasing expression of Bcl-xL and TJP1. Both 3HK and 3HAA further prevented allograft rejection by inhibiting T cell proliferation and up-regulating aryl hydrocarbon receptor expression. Pig KTx with the administration of DNA nanoparticles (DNP) that induce expression of indoleamine 2,3-dioxygenase (IDO) and KMO to increase 3HK/3HAA showed an improvement of allograft rejection as well as murine skin transplant in IDO knockout mice with the injection of 3HK indicated a dramatic reduction of allograft rejection. Taken together, our data provide strong evidence that reduction of KMO in the graft is a key mediator of allograft rejection and loss. KMO can effectively improve allograft outcome by attenuating allograft rejection and maintaining graft barrier function.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Article number

671025

Journal (Volume, Issue Number)

Frontiers in immunology (Volume 12)

Publication milestones

  • Published - 07/07/2021

Publication status

Published - 07/07/2021

Publication IDs

  • Scopus: 85111056180
  • PubMed: 34305900

Publication metrics

Metrics

Scopus
citations
Fractional count
2
Fractional count
0.50
Fractional count
2
Fractional count
0.50
Fractional count
2
Fractional count
1

PlumX, opens in new tab

Captures
14
Citation count
6

Funding Details

This work was supported in part by grants from the Carlos and Marquerite Mason Charitable Trust and Reserve Research grant fund #S-2444 from Dialysis Clinic. Inc.
FundersFunding number
Carlos and Marquerite Mason Charitable Trust
-2444
DCI
-